Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday ...

Illumina’s fair value estimate has been adjusted slightly, moving from US$135.94 to US$136.05, signaling only a very modest change in the modeled price target. That small shift sits against a backdrop ...

Illumina aims to transform human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...

Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the letter ...